Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer

Gene Therapy

Volumn 12, Issue 19, 2005, Pages 1417-1423

  Worthington, J ^a   Robson, T ^b   Scott, S ^c   Hirst, D ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cancer gene therapy; CArG elements; Inducible nitric oxide synthase

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; EARLY GROWTH RESPONSE FACTOR 1; NITRIC OXIDE SYNTHASE; NITRITE; PHENYLEPHRINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTERY; ARTICLE; CANCER; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENDOTHELIUM CELL; EX VIVO STUDY; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TUMOR GROWTH; VASOCONSTRICTION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CYTOMEGALOVIRUS; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE THERAPY; GENETIC VECTORS; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MICE; MICE, INBRED C3H; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHATIDYLETHANOLAMINES; PROMOTER REGIONS (GENETICS); RATS; RATS, WISTAR; TRANSDUCTION, GENETIC; TRANSFECTION; TRANSGENES;

CUCUMBER MOSAIC VIRUS; MURINAE;

EID: 27144458794     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302552     Document Type: Article

References (40)

1. Kramer MG et al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther 2003; 7: 375-385.
2. McArt JA et al. Development of a melanoma-specific adenovirus. Mol Ther 2002; 6: 471-480.
3. Liu BH et al. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. Gene Therapy 2004; 11: 52-60.
4. Abdul-Ghani R et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2000; 2: 539-544.
5. Cao G et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Therapy 1999; 6: 83-90.
6. Cowen RL et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: Reversing tumor radioresistance and effecting cure. Cancer Res 2004; 64: 1396-1402.
7. Guilhon E et al. Image-guided control of transgene expression based on local hyperthermia. Mol Imaging 2003; 2: 1-7.
8. Li GC et al. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res 2003; 63: 3268-3274.
9. Kufe D, Weichselbaum R. Radiation therapy: Activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther 2003; 2: 326-329.
10. Chtarto A et al. Minocycline-induced activation of tetracycline-responsive promoter. Neurosci Lett 2003; 352: 155-158.
11. Worthington J et al. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Therapy 2000; 7: 1126-1131.
12. Worthington J, Robson T, O'Keefe M, Hirst DG. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: A novel suicide gene therapy. Gene Therapy 2002; 9: 263-269.
13. Worthington J et al. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 2004; 6: 673-680.
14. Datta R et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 1992; 89 10149-11053.
15. Takahashi T, Namiki Y, Ohno T. Induction of the suicide HSV-TK gene by activation of the Egr-1 promoter with radioisotopes. Human Gene Ther 1997; 8: 827-833.
16. Hallahan D et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-791.
17. Seung LP et al. Genetic radiotherapy overcomes tumour resistance to cytotoxic agents. Cancer Res 1995; 55: 5561-5565.
18. Marples B et al. Development of synthetic promoters for radiation-mediated gene therapy. Gene Therapy 2000; 7: 511-517.
19. Marples B, Greco O, Joiner M, Scott S. Molecular approaches to chemo-radiotherapy. Eur J Cancer 2002; 38: 231-239.
20. Scott S, Joiner M, Marples B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Therapy 2002; 9 1396-1402.
21. Greco O et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Therapy 2002; 9: 1403-1411.
22. Datta R et al. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 2419-2422.
23. Mitchell JB et al. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 1993; 53: 5845-5848.
24. Griffin RJ, Makepeace CM, Hur WJ, Song CW. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int J Radiat Oncol Biol Phys 1996; 36: 377-383.
25. Kurimoto M et al. Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents. J Neurooncol 1999; 42: 35-44.
26. Chung HT et al. Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun 2001; 282: 1075-1079.
27. Van de Casteele M, Hosli M, Sagesser H, Reichen J. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats. J Hepatol 1999; 31: 300-305.
28. Robson T, Hirst DG. Transcriptional targeting in cancer gene therapy. J Biomed Biotech 2003; 2: 110-137.
29. Greco O, Marples B, Joiner M, Scott S. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 2003; 197: 312-325.
30. Weichselbaum RR, Hallahan D, Fuks Z, Kufe D. Radiation induction of immediate early genes: Effectors of the radiation-stress response. Int J Radiat Oncol Biol Phys 1994; 30: 229-234.
31. Wang Z et al. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res 2004; 64: 1386-1395.
32. Karihtala P, Kinnula VL, Soini Y. Antioxidative response for nitric oxide production in breast carcinoma. Oncol Rep 2004; 12: 755-759.
33. Kao CL et al. Elevated nitric oxide levels in childhood brain tumors. Childs Nerv Syst 2003; 19: 744-749.
34. Wang J et al. Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urol Oncol 2003; 21: 117-122.
35. Gallo O et al. Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. Am J Pathol 2003; 163: 723-732.
36. Chung P et al. Overexpression of the human inducible nitric oxide synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanism. Nitric Oxide 2003; 8 119-126.
37. Khare PD et al. Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene. Anticancer Res 2002; 22: 2443-2446.
38. Heigold S et al. Nitric oxide mediates apoptosis induction selectively in transformed fibroblasts compared to nontransformed fibroblasts. Carcinogenesis 2002; 23: 929-941.
39. Hemmrich K, Suschek CV, Lerzynski G, Kolb-Bachofen V. iNOS activity is essential for endothelial stress gene expression protecting against oxidative damage. J Appl Physiol 2003; 95: 1937-1946.
40. Suschek CV et al. Even after UVA-exposure will nitric oxide protect cells from reactive oxygen intermediate-mediated apoptosis and necrosis. Cell Death Differ 2001; 8: 515-527.